Small cell lung cancer metastatic

6 trials 2 recruiting MedDRA PT
6 Registered trials
2 Recruiting
6 Unique sponsors
8 Unique IMPs
2 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 2
— ATC code not specified 4
Mechanism of action (INN-stem analysis)
Checkpoint inhibitor (PD-L1) 2 substances
Unknown / small molecule 2 substances
Platinum compound 2 substances
Monoclonal antibody (rat) 1 substance
Topoisomerase II inhibitor 1 substance
Phase III: 1 Phase II: 3 Phase I/II: 1 Phase I (Other): 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

1 trial
  • BioNTech SE Commercial
    ATEZOLIZUMAB; BNT327
    2024-515765-34-00 7 countries 2026 n=249
    Recruiting

Phase II

3 trials
  • Academisch Ziekenhuis Maastricht Academic
    TARLATAMAB
    2025-522162-75-00 1 country n=35
    Pending
  • AIO-Studien gGmbH Academic
    TARLATAMAB
    2025-522437-65-00 1 country 2026 n=57
    Recruiting
  • Universitaet Des Saarlandes Academic
    CARBOPLATIN; CISPLATIN; DURVALUMAB; ETOPOSIDE
    2024-517937-41-00 1 country n=43
    Pending

Phase I/II

1 trial
  • Idp Discovery Pharma S.L. Commercial
    IDP-121
    2025-521902-17-00 1 country n=60
    Pending

Phase I (Other)

1 trial
  • Institut De Cancerologie De L Ouest Academic
    IMP not specified
    2024-514057-30-00 1 country n=15
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
BioNTech SE Commercial 1 Phase III 1
Idp Discovery Pharma S.L. Commercial 1 Phase I/II 0
Institut De Cancerologie De L Ouest Academic 1 Phase I (Other) 0
Academisch Ziekenhuis Maastricht Academic 1 Phase II 0
AIO-Studien gGmbH Academic 1 Phase II 1
Universitaet Des Saarlandes Academic 1 Phase II 0
New trials by year
2026
2
← All indication landscapes